Oxford BioDynamics' cancer test influences treatment decisions in study

Oxford BioDynamics (AIM:OBD) announced strong interim results from its FDA-registered PROWES trial for the EpiSwitch CiRT blood test, which influenced immunotherapy treatment decisions in 61% of cases with 85% accuracy. The blood-based diagnostic accurately predicts patient response, allowing nearly half of 'low probability' patients to avoid ineffective treatments and three-quarters of 'high probability' patients to continue or escalate therapy. This less invasive test offers significant cost-saving potential by preventing unnecessary treatments, which can exceed $850,000 per patient, and OBD plans to seek inclusion in US National Comprehensive Cancer Network guidelines, potentially driving wider market adoption.

Analysis

Oxford BioDynamics Plc (AIM:OBD) has published strongly positive interim results from its FDA-registered PROWES trial for the EpiSwitch CiRT blood test, demonstrating significant clinical utility and high predictive accuracy. The study found the test influenced immunotherapy treatment decisions in 61% of the 205-patient cohort. The test's diagnostic performance is robust, with stated figures of 93% sensitivity, 82% specificity, and 85% overall accuracy in predicting patient response to immune checkpoint inhibitors. This allows for a more personalized approach, with nearly half of patients deemed 'Low Probability of Response' avoiding potentially ineffective treatment. A key differentiating factor is that CiRT is a blood-based test, offering a less invasive and more accessible alternative to tissue biopsies. The potential for substantial cost savings, given immunotherapy courses can exceed $850,000 per patient, and early indications of its utility in monitoring emerging treatment resistance further strengthen its value proposition. A major upcoming catalyst is the company's plan to seek inclusion in the US National Comprehensive Cancer Network (NCCN) clinical guidelines later this year, which, if successful, would significantly accelerate market adoption and reimbursement.

Key Decisions for Investors

• The positive interim trial data substantially de-risks the clinical utility of the EpiSwitch CiRT test, and investors might consider this a validation of the technology's commercial potential.
• The most significant near-term catalyst is the planned application for inclusion in the US National Comprehensive Cancer Network guidelines; the outcome of this will be a pivotal driver for market adoption and should be closely monitored.
• Investors should track the progress of commercialization, particularly the company's efforts to secure broader reimbursement coverage beyond current private availability, as this will directly determine future revenue velocity.